+ everolimus (n=12), exemestane + entinostat (n=2), or fulvestrant + palbociclib (n=2). The most common regimens after progression on palbociclib were single-agent capecitabine (n=21), eribulin (n=16), nab-paclitaxel (n=15), and exemestane + everolimus (n=12
Search Results
Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma
Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force
cyclophosphamide followed by paclitaxel. 35 These results support the hypothesis that the pro-proliferative/pro-angiogenic/pro-apoptotic/ invasive signals characteristic of dysregulated c-myc genes 42 acting in concert with the anti-apoptotic signals associated
Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride
analysis included adult patients diagnosed with mNSCLC who initiated nab-paclitaxel, sb-paclitaxel, or PD-L1 based 1L therapy from 1/1/2011 to 12/31/2017. Patients were continuously enrolled (CE) with medical and pharmacy benefits ≥6 months prior to mNSCLC
Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson
Background : Pembrolizumab+chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) was recently granted FDA and EMA approval for first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer
Mary Cianfrocca and William J. Gradishar
cancer: phase III trial results . J Clin Oncol 2002 ; 20 : 2812 – 2823 . 4. O'Shaughnessy J Nag S Calderillo-Ruiz G . Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced or Recurrent Endometrioid Endometrial
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced-Stage or Recurrent Endometrioid Endometrial
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced-Stage or Recurrent Endometrioid Endometrial
Harold J. Burstein
regimens dramatically. In fact, you only need 1: AC (doxorubicin/cyclophosphamide) followed by paclitaxel. Here is the following evidence. The Oxford overview, based on treatment of over 100,000 women in adjuvant trials, suggests that all women who need
Augustine Lau, Jessy Delaisla, Jeff Dang, Sang Chau, and Andrew Hertler
control group. For those with advanced squamous NSCLC, the addition of pembrolizumab to paclitaxel/nab-paclitaxel with carboplatin provided a 6.4 months PFS advantage versus 4.8 months in the control group. Methods: The sample was obtained from a
